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Abstract
The aim of this study was to determine the frequency of erm genes coding for macrolide resistance among clinical isolates of non-pig-
mented rapidly growing mycobacteria (NPRGM) and to evaluate their importance in phenotypic resistance. Broth microdilution suscep-
tibility testing was performed for all NPRGM tested. A PCR assay with consensus primers was used to evaluate the presence of erm
genes among the 167 clinical isolates studied, which belonged to nine species of NPRGM; erm genes were detected in all nine species
and 109 strains were erm-positive. The highest percentage of erm-positive isolates was found among Mycobacterium mageritense (100%)
and the lowest among Mycobacterium mucogenicum (14%). The MICs of macrolides were found to be lower for erm-negative isolates
(MIC90: 2 mg/L) than for erm-positive isolates (MIC90: 16 mg/L), although in some cases high MICs were found for erm-negative isolates.
The ﬁnding that erm methylases are present in the majority of the species of NPRGM analysed in this study is not in agreement with
conventional susceptibility studies. It therefore appears necessary to use a combination therapy to treat infections caused by NPRGM.
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Introduction
Treatment of infections caused by non-tuberculous mycobac-
teria is complicated because each species requires a different
therapeutic approach [1]. Among these organisms, non-pig-
mented rapidly growing mycobacteria (NPRGM) have speciﬁc
susceptibility characteristics. Treatment modalities for infec-
tions with NPRGM include antimicrobials different from
those commonly used to treat infections caused by other
bacteria (i.e. quinolones, b-lactams or aminoglycosides other
than streptomycin) [2–4]. Macrolides are among the antibiot-
ics most commonly used for NPRGM infections [4,5]. These
drugs have been used either alone or in combination with
other drugs (especially amikacin). However, resistance
against these drugs has been described and, in some cases,
resistance can develop during monotherapy [6–8].
A recent report examined the molecular mechanisms
involved in macrolide resistance among these mycobacteria,
in which different erm genes appear to be common and
methylase production appears to be inducible [9]; the lack of
correlation between phenotypic resistance and molecular
detection of erm was also described.
Here, we report the evaluation of the presence of erm
genes among clinical isolates of NPRGM and the correlation
between the presence of these determinants and the suscep-
tibility phenotype.
Materials and Methods
Clinical isolates of NPRGM were studied. Species identiﬁca-
tion was achieved using several biochemical tests (nitrate
reduction, 3-day arylsulphatase, growth on McConkey agar
without crystal violet, use of citrate, mannitol, inositol, sorbi-
tol and rhamnose as carbon sources, and growth in the pres-
ence of NaCl (5%)) and PCR-restriction enzyme analysis
(PRA) of the hsp65 gene. Collection strains Mycobacterium
fortuitum ATCC 6841T, Mycobacterium chelonae ATCC
35752T, Mycobacterium abscessus DSM 44196T, Mycobacterium
peregrinum ATCC 14467T, Mycobacterium mucogenicum DSM
44124, Mycobacterium septicum ATCC 700731T, Mycobacte-
rium mageritense ATCC 700351T, Mycobacterium porcinum
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ATCC 33776T and Mycobacterium alvei ATCC 51304T were
included in the study as controls. The results of all biochemi-
cal tests as well as of the PRA proﬁles were considered nec-
essary to deﬁnitive identiﬁcation. If results of identiﬁcation
were considered doubtful or atypical, or if an isolate was of
an uncommon species (all species represented by less than
three isolates), the isolate was sent to the Mycobacteria
Reference Laboratory at the Centro Nacional de Microbio-
logı´a (Majadahonda, Spain) to conﬁrm the identiﬁcation.
Susceptibility tests were performed according to Clinical
Laboratory Standards Institute (CLSI) standards. Clarithromy-
cin was acquired from Abbott Laboratories, Inc. (Abbott Park,
IL, USA), erithromycin from Sigma-Aldrich, Inc. (St Louis,
MO, USA) and azithromycin from Pﬁzer, Inc. (Groton, CT,
USA). Concentration ranges were 0.03–64 mg/L. The CLSI
breakpoints for clarithromycin are: £ 2 mg/L for susceptible;
4 mg/L for intermediate, and ‡ 8 mg/L for resistant.
PCR analysis was performed using the consensus primers
CME-1Y (ACG TGG TGG TGG GCA AYCC TG) and
CME-2 (AAT TCG AAC CAC GGC CAC CAC T), as
described by Nash et al. [9]. The PCR protocol included the
following steps: 94 C for 2 min, followed by 25 cycles at
94 C for 30 seconds, 60 C for 30 seconds and 72 C for
30 seconds, followed by 5 min at 72 C. The reaction gave
an ampliﬁcation product of 175 bp. A negative control, with
PCR reaction mix and DNA-free sterile distilled water
(Sigma-Aldrich, Inc.), was included for every 20 reactions.
The ampliﬁed fragments were puriﬁed using the Montage
Genomics PCR Cleanup Kit (Millipore Corp., Billerica, MA,
USA). The puriﬁed fragments were sequenced in an auto-
mated sequencer (Secugen SL, Madrid, Spain). Results were
analysed using National Center for Biotechnology Informa-
tion (NCBI) nucleotide BLAST.
To calculate the correlation between phenotypic resis-
tance and the presence of erm genes we used Pearson’s cor-
relation coefﬁcient. Calculations were performed with SPSS
Version 15.0 for Windows (SPSS, Inc., Chicago, IL, USA).
Results
A total of 167 clinical isolates belonging to nine species were
included in the study (M. abscessus (9), M. alvei (2), M. chelo-
nae (30), M. fortuitum (89), M. mageritense (5), M. mucogeni-
cum (7), M. peregrinum (23), M. porcinum (1), M. septicum
(1)). The MICs for, and erm status of, all isolates are shown
in Table 1. The highest percentage of erm-positive isolates
was found among M. mageritense (100%) and the lowest
among M. mucogenicum (14%). The results for the con-
trol strains were as follows: erm genes were detected in
TABLE 1. MICs (mg/L) for clinical isolates of non-pigmented
rapidly growing mycobacteria and erm gene status
Strain Species ERY CLA AZY erm
F193 M. abscessus 0.5 £ 0.03 0.12 neg
M70 M. abscessus 2 £ 0.03 0.5 neg
M83 M. abscessus 1 £ 0.03 £ 0.03 neg
M86 M. abscessus 2 £ 0.03 2 neg
M25 M. abscessus 0.06 £ 0.03 2 pos
M24 M. abscessus 0.12 £ 0.03 0.5 pos
F95 M. abscessus > 64 32 16 pos
M1 M. abscessus 0.5 £ 0.03 0.25 pos
F64 M. abscessus 8 0.25 1 pos
M40 M. alvei > 64 4 16 neg
F108 M. alvei 32 16 > 64 pos
F172 M. chelonae 0.25 0.06 0.06 pos
F25 M. chelonae £ 0.03 0.06 0.06 neg
F43 M. chelonae 0.06 £ 0.03 0.06 neg
F176 M. chelonae 0.06 £ 0.03 0.06 neg
F82 M. chelonae 1 0.12 0.12 neg
F109 M. chelonae 32 4 1 pos
M32 M. chelonae 1 0.25 0.12 neg
M4 M. chelonae 0.25 0.06 0.25 neg
M61 M. chelonae 0.25 0.06 0.25 neg
M52 M. chelonae 0.5 0.06 0.25 neg
F51 M. chelonae 0.25 £ 0.03 0.25 neg
F44 M. chelonae 0,12 0.06 0.5 neg
F29 M. chelonae 2 0.25 0.5 neg
F83 M. chelonae 0.06 £ 0.03 0.5 neg
M16 M. chelonae 0.5 £ 0.03 2 pos
F184 M. chelonae 4 4 16 pos
M59 M. chelonae > 64 8 16 pos
F63 M. chelonae £ 0.03 £ 0.03 0.5 neg
F237 M. chelonae 1 0.06 1 neg
F224 M. chelonae 1 0.12 1 neg
M31 M. chelonae 2 0.25 1 neg
F211 M. chelonae 0.25 < 0.03 4 neg
M80 M. chelonae 0.25 £ 0.03 £ 0.03 neg
F45 M. chelonae > 64 32 > 64 pos
M94 M. chelonae 4 £ 0.03 4 pos
M30 M. chelonae 4 2 32 pos
M93 M. chelonae 16 0.25 0.5 pos
F4 M. chelonae 16 2 16 pos
F5 M. chelonae 64 2 4 pos
M14 M. chelonae £ 0.03 £ 0.03 £ 0.03 pos
M27 M. fortuitum 0.06 £ 0.03 0.5 pos
M33 M. fortuitum 0.12 0.06 1 pos
M90 M. fortuitum 0.25 £ 0.03 0.5 pos
M35 M. fortuitum 0.25 £ 0.03 1 pos
F206 M. fortuitum 1 0.12 0.25 pos
M92 M. fortuitum 1 0.06 4 pos
F207 M. fortuitum 1 0.25 £ 0.03 pos
F22 M. fortuitum 4 0.12 0.06 neg
M36 M. fortuitum 2 1 32 pos
F36 M. fortuitum 4 2 0.06 pos
F191 M. fortuitum 8 0.5 0.06 pos
M50 M. fortuitum 8 1 8 pos
F236 M. fortuitum 1 0.06 0.5 neg
M42 M. fortuitum 16 0.06 2 pos
M41 M. fortuitum 16 0.06 4 pos
M43 M. fortuitum 16 0.5 4 pos
M65 M. fortuitum > 64 4 4 pos
F5A M. fortuitum 64 16 4 pos
M75 M. fortuitum 0.5 0.12 0.5 neg
F156 M. fortuitum 32 2 0.5 neg
F233 M. fortuitum 1 £ 0.03 0.5 neg
F239 M. fortuitum 16 2 32 pos
F232 M. fortuitum 4 0.12 1 neg
M28 M. fortuitum 16 0.5 £ 0.03 pos
M23 M. fortuitum 32 2 0.12 pos
F221 M. fortuitum 32 1 0.25 pos
F250 M. fortuitum 32 2 2 pos
F295 M. fortuitum 32 2 2 pos
F24 M. fortuitum 64 4 8 pos
F92 M. fortuitum 64 4 8 pos
F257 M. fortuitum 64 4 8 pos
M51 M. fortuitum 64 4 8 pos
F8 M. fortuitum > 64 4 8 pos
F69 M. fortuitum 64 8 8 pos
F84 M. fortuitum 64 8 8 pos
F259 M. fortuitum 64 8 8 pos
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M. fortuitum ATCC 6841T, M. mageritense ATCC 700351T,
M. porcinum ATCC 33776T and M. septicum ATCC 700731T,
but not in M. abscessus DSM 44196T, M. chelonae ATCC
35752T, M. peregrinum ATCC 14467T, M. mucogenicum DSM
44124T or M. alvei ATCC 51304T. As Table 1 shows, MICs
were lower for the erm-negative isolates, although for some
isolates high MICs were observed. When the CLSI break-
points for clarithromycin are considered, ﬁve erm-negative
isolates (one M. alvei and four M. fortuitum) were intermedi-
ate (three isolates) or resistant (two isolates). By contrast,
60 erm-positive isolates appeared to be clarithromycin-sus-
ceptible, according to the previously cited criteria (four
M. abscessus, eight M. chelonae, 37 M. fortuitum, three
M. mageritense, seven M. peregrinum, and one M. septicum).
However, MICs of erythromycin were ‡ 8 mg/L for 38 of
these isolates and MICs of azithromycin were ‡ 8 mg/L for
21 isolates. The MICs of all tested macrolides were < 4 mg/
L for only 18 erm-positive isolates.
The bacterial resistance mechanisms of many bacteria have
been known for a number of years, especially for Streptococ-
cus spp. [10]. However, some resistance mechanisms among
other genera, such as mycobacteria, have been described
only recently. Although the intrinsic resistance of Mycobacte-
rium tuberculosis against macrolides is well known, the corre-
sponding molecular mechanism has been described in detail
only in the last decade [11].
It was believed that this resistance was caused by
permeability problems involving the special nature of the
mycobacterial cell wall. However, the detection of an erm
methylase (erm(37)) changes this view. Other erm methylases
have been described among various species of mycobacteria,
including NPRGM [9]. Development of resistance during
monotherapy has been described in M. chelonae, in which it
results from mutations in the peptidyltransferase region of
23S rRNA [7,8]. More recently, erm methylases have been
described in many of the species of NPRGM, including Myco-
bacterium boenickei, Mycobacterium houstonense, Mycobacterium
TABLE 1. (Continued).
Strain Species ERY CLA AZY erm
M20 M. fortuitum 32 2 2 pos
F240 M. fortuitum 4 0.25 1 neg
M17 M. fortuitum 32 1 4 pos
F242 M. fortuitum 32 4 16 pos
M15 M. fortuitum > 64 4 16 pos
M53 M. fortuitum > 64 4 16 pos
M55 M. fortuitum > 64 4 16 pos
F58 M. fortuitum > 64 8 16 pos
F255 M. fortuitum > 64 8 16 pos
F258 M. fortuitum > 64 8 16 pos
F3 M. fortuitum > 64 16 16 pos
F256 M. fortuitum 32 2 8 pos
M29 M. fortuitum 32 2 8 pos
M57 M. fortuitum 8 4 32 pos
M39 M. fortuitum 4 0.5 4 neg
M64 M. fortuitum > 64 4 16 neg
M19 M. fortuitum 64 4 32 pos
M54 M. fortuitum > 64 4 32 pos
F20 M. fortuitum 64 8 32 pos
M5 M. fortuitum > 64 8 32 pos
M9 M. fortuitum > 64 32 32 pos
F40P M. fortuitum 32 4 64 pos
F175 M. fortuitum > 64 16 64 pos
F241 M. fortuitum > 64 16 64 pos
M2 M. fortuitum > 64 16 64 pos
M66 M. fortuitum > 64 2 32 neg
M11 M. fortuitum > 64 64 32 neg
M7 M. fortuitum > 64 32 64 pos
M60 M. fortuitum > 64 4 64 neg
M8 M. fortuitum > 64 32 64 pos
M89 M. fortuitum 64 0.5 4 pos
M74 M. fortuitum 64 1 8 pos
M38 M. fortuitum 64 8 > 64 neg
M22 M. fortuitum 64 2 8 pos
F61 M. fortuitum 32 8 > 64 pos
F260 M. fortuitum > 64 8 > 64 pos
M78 M. fortuitum > 64 8 > 64 pos
M82 M. fortuitum > 64 8 > 64 pos
F56 M. fortuitum 32 16 > 64 pos
M87 M. fortuitum 0.5 £ 0.03 £ 0.03 neg
F55 M. fortuitum 64 16 > 64 pos
F194 M. fortuitum > 64 32 > 64 pos
M13 M. fortuitum > 64 32 > 64 pos
M77 M. fortuitum 64 2 8 pos
M76 M. fortuitum 64 2 16 pos
F230 M. fortuitum 64 2 32 pos
F247 M. fortuitum 64 2 64 pos
F65 M. fortuitum 64 2 > 64 pos
M91 M. fortuitum > 64 1 8 pos
M72 M. fortuitum > 64 2 16 pos
F37 M. fortuitum > 64 2 32 pos
F267 M. fortuitum > 64 2 > 64 pos
M79 M. fortuitum > 64 2 > 64 pos
M58 M. mageritense 32 2 4 pos
M69 M. mageritense 32 2 8 pos
M21 M. mageritense 64 4 16 pos
M56 M. mageritense 64 8 16 pos
M45 M. mageritense > 64 2 2 pos
M18 M. mucogenicum 0.06 £ 0.03 0.06 neg
F19 M. mucogenicum 0.06 £ 0.03 1 neg
F187 M. mucogenicum 0.06 £ 0.03 1 neg
M71 M. mucogenicum 0.5 £ 0.03 1 neg
F218 M. mucogenicum £ 0.03 £ 0.03 £ 0.03 neg
F155 M. mucogenicum 0.06 £ 0.03 £ 0.03 neg
F18 M. mucogenicum 32 16 > 64 pos
M6 M. peregrinum 0.25 £ 0.03 0.25 pos
F46 M. peregrinum 1 0.06 0.25 pos
F15 M. peregrinum 2 0.25 0.25 pos
M44 M. peregrinum 8 0.12 0.06 pos
F81 M. peregrinum 8 2 > 64 pos
M10 M. peregrinum 16 0.12 0.5 pos
F48 M. peregrinum 0.12 0.06 0.25 neg
F26 M. peregrinum 0.06 0.25 0.25 neg
M81 M. peregrinum 8 £ 0.03 0.25 neg
F272 M. peregrinum 2 0.12 0.5 neg
M12 M. peregrinum 32 0.12 0.5 neg
F53 M. peregrinum 0.5 0.06 1 neg
F213 M. peregrinum 1 0.06 1 neg
F223 M. peregrinum 2 0.25 1 neg
F274 M. peregrinum 2 0.25 1 neg
TABLE 1. (Continued).
Strain Species ERY CLA AZY erm
F273 M. peregrinum 0.12 £ 0.03 1 neg
F271 M. peregrinum 0.06 0.06 2 neg
F94 M. peregrinum 4 2 64 neg
F85 M. peregrinum 0.25 0.06 £ 0.03 neg
M3 M. peregrinum > 64 16 > 64 pos
F10 M. peregrinum 0.06 £ 0.03 £ 0.03 neg
M49 M. peregrinum 1 £ 0.03 £ 0.03 neg
M46 M. peregrinum £ 0.03 £ 0.03 £ 0.03 pos
F40G M. porcinum > 64 8 32 pos
M95 M. septicum 2 £ 0.03 0.5 pos
ERY, erithromycin; CLA, clarithromycin; AZY, azithromycin; pos, erm-positive;
neg, erm-negative.
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goodii, Mycobacterium neworleansense, M. porcinum, Mycobacte-
rium wolinskyi, M. fortuitum and Mycobacterium smegmatis [9].
These enzymes appeared to be inducible [9,12] and, in some
cases, as observed in this study, in vitro susceptibility tests
gave low MICs for these strains.
A consensus PCR based on the published erm sequences
was used. As no data are available in the literature about the
sensitivity of the PCR using these primers, and as erm
sequences differ by c. 70% [9], it is possible that other genes
coding for this type of enzyme cannot be detected with this
primer set. Apart from this uncertainty, this report includes
a higher number of clinical isolates than other reports and
presents some interesting ﬁndings.
Firstly, erm genes were detected in all species studied,
including three that have been reported as erm-negative [9]
(M. abscessus, M. chelonae and M. peregrinum) and two spe-
cies not previously studied (M. alvei and M. septicum), a ﬁnd-
ing that may reﬂect several causes. The sequencing of the
PCR fragments from M. abscessus revealed a nucleotide
sequence identity of 90–100% with erm(39), of 83–84% with
erm(38) and of 82–85% with erm(40). In M. chelonae, identity
was 94–99% with erm(39), 73–99% with erm(38) and 84%
with erm(40); in M. peregrinum it was 95–100% with erm(39)
and 95% with erm(38), according to the data obtained from
the NCBI website (http://www.ncbi.nlm.nih.gov/). This ﬁnding
is especially relevant for M. abscessus isolates because no
erm-positive isolate was reported by Nash et al. [9] and
because no orthologue of NPRGM erm genes appeared in
the recent genome sequence of the M. abscessus type strain
(Genbank accession no. CU458896) (Mycobacterium abscessus
chromosome: complete sequence; http://www.ncbi.nlm.
nih.gov/entrez/viewer.fcgi?db=nucleotide&val=NC_010397)
and our M. abscessus collection strain was erm-negative.
Several explanations can be suggested for this discrepancy.
There may be local or regional differences between strains,
as there are in other aspects of the epidemiology of these
mycobacteria. Another explanation may be that strains lose
genetic information, even resistance genes, through common
laboratory manipulations [13] (i.e. storage for long periods at
low temperatures [14]), and collection strains (including type
strains) may have fewer genes than clinical isolates. A low
number of clinical isolates, as tested by Nash et al. [9], may
also explain negative results. Finally, it may be possible that
consensus primers lack speciﬁcity and yield false-positive
PCR results. Further experiments will be needed to resolve
the discrepant results.
The presence of erm genes varied among species; it was
more frequent in the clinically relevant species M. fortuitum,
M. abscessus and M. chelonae and in M. mageritense, a spe-
cies in which enzyme production seems to be constitutive
[9]. This ﬁnding may be extremely relevant because mac-
rolides are recommended antibiotics for the therapy of
infections caused by M. chelonae and M. abscessus
[2,3,5,15], and because in some cases the presence of erm
genes was not correlated with high MIC values. In these
cases, because these enzymes are inducible, monotherapy
with macrolides may be ineffective, despite in vitro suscep-
tibility of the strains observed with standardized methods.
This, combined with the possibility that resistance may
develop through other mechanisms, makes it necessary to
treat infections caused by M. chelonae and M. abscessus
with a combination of antibiotics to which they have
proved susceptible.
Although this assumption must be conﬁrmed clinically,
according to our data a high MIC of erythromycin correlates
with the presence of erm methylases (Pearson’s correlation
coefﬁcient 0.563) better than high MICs of either clarithromy-
cin (Pearson’s correlation coefﬁcient 0.370) or azithromycin
(Pearson’s correlation coefﬁcient 0.525) do.
Otherwise, high MICs for strains in which no erm genes
are detected can be taken as unexplained as a result of low
PCR sensitivity, but they can also reﬂect the presence of
other resistance mechanisms, such as mutations in domain V
of the 23S RNA or mutations in the ribosomal proteins L4
and L22 (i.e. the absence of erm genes does not necessarily
imply macrolide susceptibility)[16].
In conclusion, erm methylases were present in all species
of NPRGM analysed in our study. This ﬁnding does not agree
with the results of conventional susceptibility studies. It is
therefore of great therapeutic importance to use a combina-
tion of several antibiotics that have been shown to be active
against the relevant clinical isolates in order to avoid the
development of resistance in vivo as a result of the presence
of these enzymes.
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